Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

NK Cell Resistance Convergence Team

Share this:
Email

Like this page on Facebook

Integrating Experimental and Computational Pipelines to Develop Biomarkers of Tumor Cell Resistance to NK Cells

Team Leader

  • Constantine S. Mitsiades MD, PhD

    Team Leader
    Assistant Professor of Medicine, at Dana-Farber Cancer Institute and Harvard Medical School, and Associate Member at the Broad Institute of MIT & Harvard
    + Full Bio

About This Team’s Research

Natural killer (NK) cells, white blood cells that play a role in viral response, have potent anti-tumor cell killing properties. Moreover, NK cells are not inhibited by many of the strategies cancer cells use to evade the immune system. This team hypothesizes that the genetic make-up of a tumor may serve as a basis to target its destruction by NK cells. To identify biomarkers that are responsible for tumor cell sensitivity or resistance NK cells, the team will use computational approaches. The team members will also explore novel interaction patterns based on NK responses by using tools such as CRISPR screens. Finally, these biomarkers will be validated on different experimental platforms such as patient-derived organoids and high-throughput systems to quantify tumor cell responses to immune effector cells. Results from this research could impact models used to study a wide range of cancers.

Click here to see a full list of Dream Team members
Click here to see the press release announcement